ABECMA (idecabtagene vicleucel) is a B-cell maturation antigen (BCMA)-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.

This website is best viewed using the horizontal display on your tablet device.

This website is best viewed using the vertical display on your mobile device.

Depend on the ABECMA® Treatment Process1

Backed by extensive real-world experience in RRMM*

The ABECMA treatment journey is multistep and involves collaboration between a primary oncologist and a certified ABECMA treatment center. Here, you can see an overview of the process. Your role is highlighted within the relevant steps below.

Defined as being in market since 2021 as the first CAR T cell therapy in RRMM.

Primary Oncologist

Certified CAR T Cell Therapy Treatment Center

Checklist with Hand Icon

Patient identification

A range of RRMM patients are eligible for treatment with ABECMA, including those who are1:

Checkmark Icon

Triple-class exposed (patients who have received an IMiD® agent, a PI, and an anti-CD38 monoclonal antibody) and who have received at least 4 prior lines of therapy

Checkmark Icon

Clinically fit (eg, good performance status and adequate organ function)

Plan ahead—identify eligible patients early and seek a consultation with a certified CAR T cell therapy treatment center to evaluate them for ABECMA.

Checklist with Hand Icon


A seamless initiation process for ABECMA

Once a patient is referred to a certified treatment center, the treatment center will evaluate patient eligibility and begin initial stages of the treatment process if appropriate.

Find a certified treatment center at

Healthcare Facility Icon

ABECMA treatment

The ABECMA treatment process1

Expand All

  • T cells are collected via leukapheresis

  • The patient’s cells are sent to a manufacturing site for engineering and expansion to the recommended dose
  • ABECMA is an autologous product; the manufactured dose for individual patients may vary
  • The patient’s dose will be 300 to 460 × 106 CAR-positive T cells
  • Bridging therapy can be used in some patients at the physician’s discretion for disease control during the manufacturing process


success rate in the pivotal study


Target turnaround time for commercial manufacturing (for >90% of batches)2‡

  • ABECMA is to be administered 2 days after completion of lymphodepletion (fludarabine [30 mg/m2 IV infusion] and cyclophosphamide [300 mg/m2 IV infusion] for 3 days)
  • Physician is notified of estimated ABECMA delivery date. Product availability should be confirmed prior to starting lymphodepletion

  • Patients are to be monitored at least daily for 7 days at the REMS-certified healthcare facility following infusion for signs and symptoms of CRS and NT
  • Patients should remain within proximity of the certified healthcare facility for at least 4 weeks following infusion for monitoring
  • A support network is important for patients throughout their experience with ABECMA
Medical Care Icon

Follow-up—Providing long-term care1

  • After at least 4 weeks of monitoring by the certified healthcare facility, the patient may return to the primary oncologist for continued monitoring and routine care appointments
  • Advise patients to refrain from driving and engaging in hazardous occupations or activities, such as operating heavy or potentially dangerous machinery, for at least 8 weeks following ABECMA infusion
  • Monitor for signs and symptoms of CRS and NT
  • Monitor CBC. Watch for signs and symptoms of serious infections, febrile neutropenia, cytopenias, and hypogammaglobulinemia
  • Monitor life-long for secondary malignancies. In the event that a secondary malignancy occurs, contact Bristol Myers Squibb at 1-888-805-4555 to obtain instructions on patient samples to collect for testing of secondary malignancy of T cell origin
  • A support network is important for patients throughout their experience with ABECMA
Information Icon

Bristol Myers Squibb has multiple FDA-approved CAR T cell therapies that utilize one centralized platform and one dedicated team with CAR T cell therapy expertise.

Learn more about ABECMA®
efficacy & safety

Find a certified
treatment center near you

The manufacturing success rate is defined as the ability to manufacture the product. The risk of manufacturing failure was 1.5% (2/135) in the pivotal study.

Manfacturing turnaround times may vary. In the pivotal study, the median time from leukapheresis to product availability was 33 days (range: 26 to 49 days) in the KarMMa study.

CAR=chimeric antigen receptor; CBC=complete blood count; CRS=cytokine release syndrome; IV=intravenous; NT=neurologic toxicity; PI=proteasome inhibitor; REMS=Risk Evaluation and Mitigation Strategy; RRMM=relapsed/refractory multiple myeloma.